ZyVersa Therapeutics (NASDAQ:ZVSA – Get Free Report) and Aprea Therapeutics (NASDAQ:APRE – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.
Risk and Volatility
ZyVersa Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for ZyVersa Therapeutics and Aprea Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ZyVersa Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Aprea Therapeutics | 1 | 1 | 3 | 0 | 2.40 |
Earnings & Valuation
This table compares ZyVersa Therapeutics and Aprea Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ZyVersa Therapeutics | N/A | N/A | -$9.41 million | ($1.34) | -0.13 |
| Aprea Therapeutics | $290,000.00 | 39.36 | -$12.60 million | ($1.54) | -0.60 |
ZyVersa Therapeutics has higher earnings, but lower revenue than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares ZyVersa Therapeutics and Aprea Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ZyVersa Therapeutics | N/A | -109.54% | -43.95% |
| Aprea Therapeutics | -4,405.59% | -61.03% | -50.24% |
Summary
Aprea Therapeutics beats ZyVersa Therapeutics on 8 of the 13 factors compared between the two stocks.
About ZyVersa Therapeutics
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Receive News & Ratings for ZyVersa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZyVersa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
